Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
UTD2 is the world's first oral epothilone microtubule inhibitor
Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg had annual sales of USD 42 mn in the United States (IQVIA MAT April 2023)
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
Farxiga is expected to have such a strong influence on the market due to the impressive results
Subscribe To Our Newsletter & Stay Updated
